One-Shot gene therapy trial launches for ALS patients

NCT ID NCT07290062

First seen Jan 02, 2026 · Last updated May 14, 2026 · Updated 23 times

Summary

This early-stage study tests a single injection of INS1202, a gene therapy, given into the spinal fluid of people with ALS. The main goal is to check safety and find the right dose. About 23 adults aged 18 to 79 with either a specific SOD1 gene mutation or no known genetic cause of ALS can join.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • USA001

    RECRUITING

    Columbia, Missouri, 65211, United States

    Contact Email: •••••@•••••

  • USA002

    RECRUITING

    Palo Alto, California, 94304, United States

    Contact Email: •••••@•••••

  • USA004

    RECRUITING

    La Jolla, California, 92037, United States

    Contact Email: •••••@•••••

  • USA006

    RECRUITING

    Philadelphia, Pennsylvania, 19107, United States

    Contact Email: •••••@•••••

  • USA007

    RECRUITING

    Columbus, Ohio, 43221, United States

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.